Summary One hundred and sixty-three breast carcinomas occurring in women aged between 26 and 44 years were examined for pathological features, oestrogen and progesterone receptor status, proliferation as determined by Ki-67 labelling and the presence of c-erbB-2 and p53 protein, and were compared with a control group of carcinomas from women in the 50-67 years age group. Carcinomas occurring in women aged under 35 years had a significantly high incidence of being poorly differentiated and of having high proliferation rates. This group also had a significantly high incidence of p53 protein staining. Carcinomas in the under 30 years age group had a lower incidence of oestrogen and progesterone receptor positivity. No differences were found in c-erbB-2-positive staining between the groups. Infiltrating lobular carcinomas were only identified in women aged 40 years and over. There was a higher incidence of a family history in the 35-44 years age group (18%) than in the under 35 years age group (11%). Breast carcinomas occurring in women aged under 35 years are more aggressive. An important finding is the high incidence of p53 positivity, which may indicate genetic instability.
There is evidence from several studies that women who develop breast cancer at a young age (either 30 years and less or 34 years and less) have lower survival rates than older patients (Wallgren et al., 1977; Ribeiro and Swindell, 1981; Noyes et al., 1982; Adami et al., 1986; Host and Lund, 1986; Sant et al., 1991; de la Rochefordiere et al., 1993; Bonnier et al., 1995; Chung et al., 1996) . The findings have not differed over a 25 year time span and have been reported from different countries. Several publications have suggested that the poorer prognosis may be related to the biological nature of the tumour (Adami et al., 1986; Host and Lund, 1986; de la Rochefordiere et al. 1993; Chung et al., 1996) . Pillers (1992) combined data on histological grading from two centres and found that there was a higher frequency of poorly differentiated carcinomas in the aged 34 years and under group.
The presence or absence of various markers is associated with poorer prognosis, e.g. the overexpression of c-erbB-2 oncoprotein (Walker et al., 1989; Gullick et al., 1991) , expression of p53 protein (Thor et al., 1992; Barnes et al., 1993) and lack of oestrogen and progesterone receptor (Foekens et al., 1989; Reiner et al., 1990) . Higher levels of proliferation as determined by Ki-67 labelling are associated with poorer prognosis (Railo et al., 1993) .
In order to determine whether there is a difference in the biological nature of breast carcinomas arising in younger women, a series has been studied for a variety of markers as well as pathological features.
Materials and methods

Patients
One hundred and fifty-eight cases of invasive carcinomas were identified from the pathology files of Leicester Royal Infirmary and Glenfield Hospital, UK, and five cases were provided by Alexandra Hospital, Redditch, UK, totalling 163. Cases who had received chemotherapy and/or radiotherapy before excision of the tumour were excluded, as this may modify the immunostaining and grading. Therefore, there were no cases included which were considered clinically to be inflammatory carcinomas. 
Pathology
Representative blocks from each case were fixed in 4% formaldehyde in saline and processed through to paraffin wax. Haematoxylin and eosin-stained sections were evaluated for type of carcinoma using the criteria published in the National Health Service (NHS) Breast Screening Guidelines (1990) . Infiltrating ductal carcinomas were graded using the modified Bloom and Richardson criteria (Elston and Ellis, 1991) , as recommended in the NHS Breast Screening Guidelines and in the guidelines of the Association of Directors of Anatomic and Surgical Pathology (1996) . Biotinylated rabbit anti-mouse immunoglobulin antiserum followed by streptavidin peroxidase was the detection system and peroxidase was localised using diaminobenzidine-hydrogen peroxide.
c-erbB-2 and p53 The antibody NCL CB 11 was applied at 1:80 for 18 h at 4°C, and was followed by biotinylated rabbit anti-mouse immunoglobulin antiserum and streptavidin peroxidase, as above. CM1 was applied at 1:100 for 18 h at 4°C and was followed by biotinylated swine anti-rabbit immunoglobulin antiserum and streptavidin peroxidase, with diaminobenzidine-hydrogen peroxide localisation. Controls were present in all instances with the omission of the primary antibody and the inclusion of a known positive in each staining batch.
Evaluation Oestrogen and progesterone receptor reactivity was categorised as negative, or as having < 10%, 10-25%, 25-50%, 50-75% and >75% positive cells, with 10% being the cut-off point between positive and negative, as described previously (Rajakariar and Walker, 1995 There was a higher incidence of node-positive cases in the under 30 years age group but the numbers in this category were small.
Immunohistochemistry
The overall results are shown in Table II .
There was a low incidence of oestrogen and progesterone receptor-positive carcinomas in the aged under 30 years group. There was no significant difference in the oestrogen and progesterone receptor results between the under 35 years and the 35-44 years age groups, between the under 35 years and control age groups, and between the 35-44 years and control groups. The range of c-erbB-2 positivity was 17.0-22.5%, and there were no significant differences between the different age groups.
The highest incidence of detecting p53 was in the under 30 years age group (67%) (Figure 1) , with a decreasing incidence with increasing age (Figure 2 differentiated infiltrating ductal carcinomas and three were p53-positive. Six of the women in the 40-44 years age group had more than one family member affected, another two women had mothers who were affected premenopausally. Ten carcinomas were infiltrating ductal (one grade I, three grade II, six grade III), one was a tubular carcinoma and another was an infiltrating lobular carcinoma. p53 was detected in four cases, a similar incidence to this age group overall.
Discussion
The study has shown that although there clearly are differences in the carcinomas arising in women aged under 35 years, the carcinomas arising in women aged 35-44 years are not significantly different from those occurring in women aged 50-67 years. This emphasises the importance of the subdivision of the under 50 years age group in any studies that consider prognostic factors.
The differences in the carcinomas encompass both pathological and biological features, although the two are probably related. The high incidence of poorly differentiated carcinomas in the under 35 years age group has been reported by others (Pillers, 1992) . It is striking that no welldifferentiated carcinomas were found in this age group and that the differentiation of carcinomas in the 35 and over age group was not significantly different from the older age group. The 35-44 years age group had a higher incidence of family history than the under 35 years age group and showed no particular relationship to tumour type, grade and p53 status.
Both oestrogen receptor status and proliferation correlate with differentiation. The presence of oestrogen receptor is associated with better differentiation (Bruun Rasmussen et al., 1981) . It is therefore not surprising that there is a low incidence of oestrogen receptor positivity in the 29 years and younger age group. This has also been reported by Albain et al. (1994) . However, 57% of the carcinomas in the 30-34 years age group were oestrogen receptor positive, a value not significantly different from the other age groups. This suggests that there are other factors determining the oestrogen receptor status as 70% of carcinomas in this group were poorly differentiated. Proliferation as determined by antigen detection relates to tumour differentiation (Walker and Camplejohn, 1988) , and high levels of labelling were seen in the two age groups with a high incidence of poorer differentiation. A high S-phase fraction was found in 60% or more of carcinomas from women 35 years and younger (Albain et al., 1994) , which is similar to the findings in this study for Infiltrating lobular carcinomas were only identified in women aged 40 years or more. Marcus et al. (1994) have reviewed the literature with regard to the pathology of early onset of breast carcinoma. They considered that there was a significant trend for less invasive lobular carcinoma in the younger age group and noted the effect to be most prominent in the 20-29 year age group. However, such a clear cut-off point at 40 years has not been reported by others.
Although c-erbB-2 expression has been related to poorer differentiation (Walker et al., 1989; Allred et al., 1992) , there was no difference in expression between the different age groups and the control. Allred et al. (1992) found a higher incidence of c-erbB-2 expression in cases of infiltrating ductal carcinoma with associated ductal carcinoma in situ, and which they found more frequently in a younger age group. However, their group (Albain et al., 1994) found no significant difference in expression across age groups.
Apart from differentiation and proliferation, the one marker which was significantly different between the under 35 years age group and the other age groups was p53, with a high incidence of 67% positive cases in the under 30 years age group. The presence of p53 protein does not necessarily imply that there is a mutation as other factors can lead to stabilisation and hence reactivity (Wynford-Thomas, 1992) . Both p53 protein staining and mutation have been associated with poorer differentiation and oestrogen and progesterone receptor-negative tumours (Walker et al., 1991; Mazars et al., 1992; Thor et al., 1992; Barnes et al., 1993; Jacquemier et al., 1994) . When age has been considered, it has usually involved the subdivision of women into under or over 50 years of age, and no significant difference has been found. Caleffi et al.
(1994) did find a significantly higher incidence of p53 mutations in younger women, using 45 years of age as the cut-off point. Albain et al. (1994) also reported a striking incidence of p53 protein in the 35 years and under age group.
Several studies have implicated p53 protein in the G,-S arrest which occurs in response to DNA damage (Kuerbitz et al., 1992; Yin et al., 1992) . p53 activates a Mr 21 000 protein (Cip/WAF1/SDI) which inhibits the activity of cyclindependent kinases and thus induces arrest in GI or apoptosis (El-Deiry et al., 1994) . Cells with abnormal p53 do not activate p21 and do not show normal G, arrest which is necessary for repair after exposure to DNA-damaging agents. In a study of 183 breast carcinomas, Eyfjord et al. (1995) found a significant association between p53 abnormalities and genetic instability.
It will be of particular interest and importance to analyse the breast carcinomas occurring in the young age group to determine whether there are any common p53 abnormalities and whether there are any associated DNA repair defects.
